Philogen Zukünftiges Wachstum
Future Kriterienprüfungen 0/6
Der Umsatz und der Gewinn von Philogen werden voraussichtlich um 83.6% bzw. 126.5% pro Jahr zurückgehen, während der Gewinn je Aktie voraussichtlich um 126.7% pro Jahr sinken wird.
Wichtige Informationen
-126.5%
Wachstumsrate der Gewinne
-126.71%
EPS-Wachstumsrate
| Biotechs Gewinnwachstum | 20.6% |
| Wachstumsrate der Einnahmen | -83.6% |
| Zukünftige Eigenkapitalrendite | n/a |
| Analystenabdeckung | Low |
| Zuletzt aktualisiert | 24 Apr 2026 |
Jüngste Aktualisierungen zum künftigen Wachstum
Recent updates
Analyse-Update • Apr 20
PHIL: Softer Earnings Outlook And 2026 Board Milestones Will Shape Repricing Potential
Analysts have reduced their price target on Philogen from €26 to €23. They point to softer revenue growth expectations, a lower projected profit margin and a higher future P/E multiple as key drivers of the revision.
Neue Analyse • Apr 09
Clinical Pipeline And Radiopharmaceutical Expansion Will Pressure Margins And Future Earnings Potential
Catalysts About Philogen Philogen develops targeted biological and small molecule therapies, primarily for oncology and certain inflammatory diseases. What are the underlying business or industry changes driving this perspective?Analyse-Update • Apr 06
PHIL: 2026 Board Calendar And Steady Assumptions Will Support Future Repricing Potential
Analysts have kept their fair value estimate for Philogen steady at €26.0 per share, citing largely unchanged assumptions on the discount rate, revenue trends, profit margin and future P/E as reasons for maintaining their price target. What's in the News Board meeting scheduled for March 27, 2026, to approve the Draft Financial Statements and the 2025 Consolidated Financial Statements (company filing) Board meeting set for May 12, 2026, to approve a press release containing a quarterly report with selected information on business performance for the first quarter of 2026 (company filing) Board meeting planned for September 23, 2026, to approve the Half-Yearly Financial Report as at June 30, 2026 (company filing) Board meeting scheduled for November 12, 2026, to approve a press release with a quarterly report providing selected information on business performance for the third quarter of 2026 (company filing) Valuation Changes Fair Value: unchanged at €26.0 per share, with no adjustment to the overall fair value estimate.Analyse-Update • Mar 23
PHIL: 2026 Board Schedule Will Support Confidence In Future Repricing Potential
Analysts have kept their price target for Philogen steady at €26.0, indicating only minimal tweaks in the discount rate and forward P/E assumptions, while leaving profit margin expectations unchanged. What's in the News Board meeting scheduled for March 27, 2026, to approve the Draft Financial Statements and the 2025 Consolidated Financial Statements (company event) Board meeting set for May 12, 2026, to approve a press release containing a quarterly report with selected information on the first quarter of 2026 (company event) Board meeting planned for September 23, 2026, to approve the Half-Yearly Financial Report as at June 30, 2026 (company event) Board meeting scheduled for November 12, 2026, to approve a press release containing a quarterly report with selected information on the third quarter of 2026 (company event) Valuation Changes Fair Value: kept steady at €26.0 per share, with no change in the central valuation level.Analyse-Update • Mar 08
PHIL: 2026 Board Timetable Will Support Confidence In Future Upside
Analysts have left their fair value estimate for Philogen steady at €26.0. They point to only minor tweaks in the discount rate and assumed future P/E that reflect updated risk and earnings assumptions rather than a shift in their overall view. What's in the News Board meeting scheduled for March 27, 2026 to approve the Draft Financial Statements and the 2025 Consolidated Financial Statements (company filing) Board meeting set for May 12, 2026 to approve the press release that will contain the quarterly report with selected information on first quarter 2026 performance (company filing) Board meeting planned for September 23, 2026 to approve the Half-Yearly Financial Report as at June 30, 2026 (company filing) Board meeting on November 12, 2026 to approve the press release that will contain the quarterly report with selected information on third quarter 2026 performance (company filing) Valuation Changes Fair Value: Kept steady at €26.0 per share, with no change in the headline estimate.Analyse-Update • Feb 21
PHIL: 2026 Board Milestones Will Support Confidence In Future Upside
Analysts have made only a marginal adjustment to their valuation framework for Philogen, keeping the fair value anchor steady at around €26 while fine tuning inputs such as the discount rate, revenue growth assumptions and future P/E to reflect updated risk and earnings expectations. What's in the News Board meeting scheduled for March 27, 2026, to approve the draft financial statements and the 2025 consolidated financial statements (company event calendar).Analyse-Update • Feb 06
PHIL: Upcoming Trial Readouts And 2026 Milestones Will Support Upside Potential
Narrative Update on Philogen Analysts now set their price target for Philogen at €26.00, broadly in line with the prior €26 level. This reflects modestly lower discount rate and future P/E assumptions that fine tune their view of the company’s risk and valuation profile.Analyse-Update • Jan 23
PHIL: Future Sarcoma Trial Data Will Support Upside Potential
Analysts have modestly lifted their price target for Philogen to €26.00 per share, reflecting small tweaks to their discount rate and long term P/E assumptions, while keeping fair value otherwise unchanged. What's in the News Philogen provided an update on the FIBROSARC Phase III trial, which tests fibromun plus doxorubicin versus doxorubicin alone as first line treatment for advanced or metastatic soft tissue sarcoma.Analyse-Update • Jan 08
PHIL: Future Sarcoma Trial Data Will Support Upside Potential
Analysts have adjusted their price target for Philogen to €26.00. The change reflects slightly higher perceived risk through a modestly higher discount rate and a broadly unchanged outlook for margins and future P/E assumptions.Analyse-Update • Dec 19
PHIL: Future Sarcoma Trial Progress Will Support Upside From Current Levels
Analysts have nudged their price target on Philogen slightly higher to €26.00. This reflects unchanged assumptions on fair value, discount rate, and long term profitability, while acknowledging the resilience of the company’s margin outlook despite subdued growth expectations.Analyse-Update • Dec 05
PHIL: Future Trial Milestones And Buyback Activity Will Support Fair Value
Analysts have modestly raised their price target on Philogen to €26.00 per share, reflecting improved expectations for long term profit margins and valuation multiples, despite slightly lower near term revenue growth forecasts. What's in the News Philogen reported updated data from its FIBROSARC Phase III trial of fibromun plus doxorubicin in advanced or metastatic soft tissue sarcoma, with primary endpoint progression free survival and plans to present full results at scientific conferences and in a peer reviewed journal in 2026 (Key Developments).Analyse-Update • Nov 20
PHIL: Share Buyback and Stable Financials Will Support Current Fair Value
Narrative Update on Philogen Analysts have maintained their price target for Philogen at €26.00. They cite continued confidence in the company’s outlook despite only minor adjustments to valuation inputs.Analyse-Update • Nov 05
PHIL: Share Buyback and Stable Metrics Expected to Sustain Fair Value
Narrative Update: Philogen Price Target Revision Analysts have maintained Philogen's fair value estimate at €26.00. Adjustments in future revenue growth and profit margin expectations are key supporting factors for this unchanged target.Analyse-Update • Oct 22
Analysts Maintain €26 Target for Philogen as Buyback and Valuations Remain Stable
Analysts have maintained their price target for Philogen at €26.00 per share, citing stable expectations for key financial metrics and future performance. What's in the News Philogen completed the repurchase of 29,448 shares, representing 0.07% of total shares, for €0.66 million under the buyback program announced on May 12, 2025 (Key Developments).Analyse-Update • Oct 08
Late-stage Approvals Plus Sun Pharma Will Transform Oncology Despite Risks
Analysts have lowered their price target for Philogen from $28.00 to $26.00. This decision is based on revisions in revenue growth projections and a significant reduction in estimated profit margins.Analyseartikel • Oct 04
Philogen's (BIT:PHIL) Earnings Aren't As Good As They Appear
Despite posting strong earnings, Philogen S.p.A.'s ( BIT:PHIL ) stock didn't move much over the last week. We decided...Neue Analyse • Aug 20
Late-stage Approvals Plus Sun Pharma Will Transform Oncology Despite Risks
Key Takeaways Advancing late-stage therapies and strategic pharma partnerships position Philogen for recurring product sales, stronger margins, and reduced funding risk through enhanced cash flow visibility. Alignment with personalized medicine trends and a robust cash position support long-term growth, innovation, and protection of shareholder value amid rising global demand for oncology solutions.Analyseartikel • Apr 14
Analyst Forecasts For Philogen S.p.A. (BIT:PHIL) Are Surging Higher
Philogen S.p.A. ( BIT:PHIL ) shareholders will have a reason to smile today, with the analysts making substantial...Analyseartikel • Mar 31
Earnings Update: Philogen S.p.A. (BIT:PHIL) Just Reported And Analysts Are Boosting Their Estimates
Philogen S.p.A. ( BIT:PHIL ) last week reported its latest yearly results, which makes it a good time for investors to...Analyseartikel • Feb 24
What Philogen S.p.A.'s (BIT:PHIL) P/S Is Not Telling You
You may think that with a price-to-sales (or "P/S") ratio of 25.1x Philogen S.p.A. ( BIT:PHIL ) is a stock to avoid...Analyseartikel • Jun 03
Here's Why We're Watching Philogen's (BIT:PHIL) Cash Burn Situation
We can readily understand why investors are attracted to unprofitable companies. For example, although...Gewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 12/31/2028 | 66 | N/A | N/A | N/A | 1 |
| 12/31/2027 | 41 | -18 | -28 | -28 | 3 |
| 12/31/2026 | 54 | -46 | -32 | -31 | 3 |
| 12/31/2025 | 320 | 230 | 264 | 268 | N/A |
| 9/30/2025 | 202 | 138 | 151 | 154 | N/A |
| 6/30/2025 | 85 | 46 | 37 | 40 | N/A |
| 3/31/2025 | 81 | 46 | 38 | 40 | N/A |
| 12/31/2024 | 77 | 45 | 38 | 41 | N/A |
| 9/30/2024 | 41 | 8 | 4 | 8 | N/A |
| 6/30/2024 | 4 | -29 | -31 | -25 | N/A |
| 3/31/2024 | 14 | -18 | -21 | -15 | N/A |
| 12/31/2023 | 25 | -6 | -11 | -5 | N/A |
| 9/30/2023 | 27 | -3 | -7 | -3 | N/A |
| 6/30/2023 | 29 | 0 | -3 | -1 | N/A |
| 3/31/2023 | 28 | -3 | -6 | -3 | N/A |
| 12/31/2022 | 27 | -5 | -9 | -5 | N/A |
| 9/30/2022 | 25 | -5 | -9 | -4 | N/A |
| 6/30/2022 | 23 | -5 | -9 | -2 | N/A |
| 3/31/2022 | 14 | -10 | -17 | -11 | N/A |
| 12/31/2021 | 5 | -16 | -26 | -19 | N/A |
| 9/30/2021 | 6 | -14 | -26 | -19 | N/A |
| 6/30/2021 | 6 | -14 | -25 | -18 | N/A |
| 3/31/2021 | 6 | -13 | -21 | -16 | N/A |
| 12/31/2020 | 6 | -13 | -17 | -13 | N/A |
| 9/30/2020 | 8 | -11 | -15 | -12 | N/A |
| 12/31/2019 | 15 | 1 | 6 | 7 | N/A |
| 12/31/2018 | 16 | 4 | N/A | 5 | N/A |
| 12/31/2017 | 14 | 3 | N/A | -7 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: PHILFür die nächsten 3 Jahre wird ein Rückgang der Gewinne prognostiziert (-126.5% pro Jahr).
Ertrag vs. Markt: PHILFür die nächsten 3 Jahre wird ein Rückgang der Gewinne prognostiziert (-126.5% pro Jahr).
Hohe Wachstumserträge: PHILFür die nächsten 3 Jahre wird mit einem Rückgang der Erträge gerechnet.
Einnahmen vs. Markt: PHILDie Einnahmen des Unternehmens werden in den nächsten 3 Jahren voraussichtlich zurückgehen (-83.6% pro Jahr).
Hohe Wachstumseinnahmen: PHILDie Einnahmen des Unternehmens werden in den nächsten drei Jahren voraussichtlich zurückgehen (-83.6% pro Jahr).
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von PHIL in 3 Jahren voraussichtlich hoch sein wird
Wachstumsunternehmen entdecken
Unternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/05/08 03:04 |
| Aktienkurs zum Tagesende | 2026/05/08 00:00 |
| Gewinne | 2025/12/31 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Philogen S.p.A. wird von 4 Analysten beobachtet. 3 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Rajan Sharma | Goldman Sachs |
| Victor Floch | Stifel, Equities Research |
| Clemence Thiers | Stifel, Equities Research |